Month: September 2023

With reference to the announcement 27 September 2023, and the presentation held Thursday 28 September 2023, we haveattached an updated Investor presentation.  About Ensurge Micropower  Ensurge is Energizing Innovation(TM) with the first ultrathin, flexible, reliable, and fundamentally safe solid-state lithium microbattery for the 1 to 100 milliampere-hour (mAh) class of wearable devices, connected sensors, and beyond. The innovative Ensurge Microbattery enables energy-dense rechargeable products that are ideal for form-factor-constrained applications including hearables (hearing aids and wireless headphones), digital and health wearables, sports and fitness devices, and IoT sensor solutions that use energy harvesting to power everyday things. The company’s state-of-the-art manufacturing facility, located in the heart of Silicon Valley,...

Latest edition of Haleon Pain Index finds half (49%) of people in pain feel stigmatised[1][2] 42% regularly feel lonely due to their pain, and one third feel serious loneliness (based on UCLA loneliness scale)[3] 32% of people living in pain fear they will be judged Women, people of colour and the LGBQ+ community are worst affected Gen Z more likely to feel unheard than Baby BoomersLONDON, Sept. 28, 2023 (GLOBE NEWSWIRE) — A new study of 18,097 people across 18 countries has discovered that society has grown less tolerant of people in pain, despite the effects of COVID-19 boosting global health awareness. The fifth edition of the Haleon Pain Index (HPI)[1], conducted by consumer health company Haleon, suggests that attitudes towards pain in post-pandemic society are now more judgemental and less tolerant, with half (49%) of...

Banks must harness emerging technologies and create or participate in digital ecosystems to remain at the center of the banking universe, according to the report GENEVA, Switzerland, Sept. 28, 2023 (GLOBE NEWSWIRE) — Banks must harness disruptive technologies and create their own or actively participate in digital ecosystems to remain at the heart of the banking universe, according to a global Economist Impact study, commissioned by Temenos, which surveyed 300 banks across the globe. The report, “Byte-sized banking: Can banks create a true ecosystem with embedded finance?” finds that payment companies, technology and e-commerce disruptors are competing against banks with embedded finance solutions. Coupled with consumers’ growing expectations for better, more personalized products and services, this is forcing banks to assess the...

Share Buyback Transaction Details September 21 – September 27, 2023 September 28, 2023 – Wolters Kluwer (Euronext: WKL), a global leading provider of expert solutions, insights and services for professionals, today reports that it has repurchased 215,701 of its own ordinary shares in the period from September 21, 2023, up to and including September 27, 2023, for €24.6 million and at an average share price of €114.09. These repurchases are part of the share buyback program announced on February 22, 2023, under which we intend to repurchase shares for up to €1 billion during 2023. The cumulative amounts repurchased to date under this year’s buyback program are as follows: Share Buyback 2023Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2023 to date...

Bids, sales, stop-rates and prices are presented in the table below:      ISIN Bid Mill. kr. (nominal) Sale Stop-rate (per cent) Pro-rata Price98 19153 DKT 01/12/23 IV 1,100 100 3.540 100 % 99.413598 19237 DKT 01/03/24 I 3,700 2,500 3.545 100 % 98.5349Total 4,800 2,600      The sale will settle 2 October 2023

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to be presented by the end of 2023 SOUTH SAN FRANCISCO, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) — Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the presentation of interim data for the 2.15 to 12 mg target dose cohorts from its Phase 1 clinical trial evaluating single-agent HPN217 in relapsed/refractory multiple myeloma (RRMM). HPN217 targets B-cell maturation antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient’s immune cells to kill tumor cells....